|
Apr 2
|
Biotech With 520% Sales Growth Nears Next Buy Point
|
|
Mar 22
|
Two Health Care Stocks Outperform S&P 500, Offer Entries
|
|
Mar 22
|
Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?
|
|
Mar 22
|
Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?
|
|
Mar 22
|
Ascendis Pharma A/S (ASND) Rose on Positive Trial Results
|
|
Mar 17
|
30 Biggest Biotechnology Companies in the World
|
|
Mar 11
|
The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys
|
|
Mar 8
|
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
|
|
Mar 7
|
Ascendis Pharma A/S (ASND) Faced R&D Setbacks in Q4
|
|
Mar 6
|
Is AdaptHealth (AHCO) Stock Outpacing Its Medical Peers This Year?
|
|
Mar 4
|
Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024
|
|
Jan 29
|
New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors
|
|
Jan 10
|
Investors ignore increasing losses at Ascendis Pharma (NASDAQ:ASND) as stock jumps 11% this past week
|
|
Jan 8
|
Vector Pharma FZCO Announce Exclusive Distribution Agreement with Ascendis Pharma A/S for Skytrofa (lonapegsomatropin) and Yorvipath (palopegteriparatide) in Gulf Cooperation Council Countries
|
|
Jan 7
|
Ascendis Pharma Introduces Vision 2030
|
|
Jan 7
|
Specialised Therapeutics signs exclusive agreement with Ascendis Pharma A/S for distribution and commercialisation of three endocrinology therapies in Australia and select South-East Asia countries
|
|
Dec 20
|
Significant Health and Quality of Life Improvements Achieved in Children with Achondroplasia Treated for One Year with TransCon™ CNP (Navepegritide) at 100 µg/kg/week
|
|
Dec 19
|
TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency
|
|
Nov 29
|
Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan
|
|
Nov 20
|
Ascendis Pharma Announces European Commission Approval of YORVIPATH® (palopegteriparatide) for the Treatment of Adults with Chronic Hypoparathyroidism
|